Top

Published in:

01-01-2020 | Metastasis | Review Article

Friend or foe, the role of EGR-1 in cancer

Authors: Tong-tong Li, Man-ru Liu, Dong-sheng Pei

Published in: Medical Oncology | Issue 1/2020

Abstract

Early growth response-1 (EGR-1), also termed NEFI-A and Krox-24, as a multi-domain protein is implicated in several vital physiological processes, including development, metabolism, cell growth and proliferation. Previous studies have implied that EGR-1 was producing in response to the tissue injury, immune response and fibrosis. Meanwhile, emerging studies stressed the pronounced correlation of EGR-1 and human cancers. Nevertheless, the intricate mechanisms of cancer-reduce EGR-1 alteration still poorly characterized. In the review, we evaluated the effects of EGR-1 in tumor cell proliferation, apoptosis, migration, invasion and tumor microenvironment, and then, we dwell on the intricate signaling pathways that EGR-1 involved in. The aberrantly expressed of EGR-1 in cancers are expected to provide a new cancer therapy strategy or a new marker for assessing treatment efficacy.

Bhattacharyya S, Fang F, Tourtellotte W, Varga J. Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis). J Pathol. 2013;229(2):286–97. https://doi.org/10.1002/path.4131.CrossRefPubMed

Pagel JI, Deindl E. Disease progression mediated by egr-1 associated signaling in response to oxidative stress. Int J Mol Sci. 2012;13(10):13104–17. https://doi.org/10.3390/ijms131013104.CrossRefPubMedPubMedCentral

Braddock M. The transcription factor Egr-1: a potential drug in wound healing and tissue repair. Ann Med. 2001;33(5):313–8.CrossRef

Thiel G, Rossler OG. Resveratrol regulates gene transcription via activation of stimulus-responsive transcription factors. Pharmacol Res. 2017;117:166–76. https://doi.org/10.1016/j.phrs.2016.12.029.CrossRefPubMed

Nag JK, Bar-Shavit R. Transcriptional landscape of PARs in epithelial malignancies. Int J Mol Sci. 2018;19(11):E3451. https://doi.org/10.3390/ijms19113451.CrossRefPubMed

Rettino A, Rafanelli F, Genovese G, Goracci M, Cifarelli RA, Cittadini A, Sgambato A. Identification of Sp1 and GC-boxes as transcriptional regulators of mouse Dag1 gene promoter. Am J Physiol Cell Physiol. 2009;297(5):C1113–23. https://doi.org/10.1152/ajpcell.00189.2009.CrossRefPubMed

Li H, Chen D, Zhang J. Analysis of intron sequence features associated with transcriptional regulation in human genes. PLoS ONE. 2012;7(10):e46784. https://doi.org/10.1371/journal.pone.0046784.CrossRefPubMedPubMedCentral

Courey AJ, Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell. 1988;55(5):887–98.CrossRef

Huang RP, Fan Y, Ni Z, Mercola D, Adamson ED. Reciprocal modulation between Sp1 and Egr-1. J Cell Biochem. 1997;66(4):489–99.CrossRef

10.

Ahmed MM, Sells SF, Venkatasubbarao K, et al. Ionizing radiation-inducible apoptosis in the absence of p53 linked to transcription factor EGR-1. J Biol Chem. 1997;272:33056–61.CrossRef

11.

Virolle T, Adamson ED, Baron V, et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol. 2001;3:1124–8. https://doi.org/10.1038/ncb1201-1124.CrossRefPubMed

12.

Shi Q. Resveratrol-responsive CArG elements from the Egr-1 promoter for the induction of GADD45α to arrest the G2/M transition. Methods Mol Biol. 2019;1895:111–22. https://doi.org/10.1007/978-1-4939-8922-5_9.CrossRefPubMed

13.

Wong KE, Ngai SC, Chan KG, et al. Curcumin nanoformulations for colorectal cancer: a review. Front Pharmacol. 2019;10:152. https://doi.org/10.3389/fphar.2019.00152.CrossRefPubMedPubMedCentral

14.

Auyeung KK, Cho CH. A novel anticancer effect of Astragalus saponins: transcriptional activation of NSAID-activated gene. Int J Cancer. 2009;125:1082–91. https://doi.org/10.1002/ijc.24397.CrossRefPubMed

15.

Secchiero P, Rimondi E, di Iasio MG, et al. C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway. Clin Cancer Res. 2013;19:1949–59. https://doi.org/10.1158/1078-0432.ccr-12-3027.CrossRefPubMed

16.

Thiel J, Alter C, Luppus S, et al. MicroRNA-183 and microRNA-96 are associated with autoimmune responses by regulating T cell activation. J Autoimmun. 2019;96:94–103. https://doi.org/10.1016/j.jaut.2018.08.010.CrossRefPubMed

17.

Wang WD, Li R, Chen ZT, et al. Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements. Cancer Sci. 2005;96:706–12. https://doi.org/10.1111/j.1349-7006.2005.00105.x.CrossRefPubMed

18.

Lim JH, Park JW, Min DS, et al. NAG-1 up-regulation mediated by EGR-1 and p53 is critical for quercetin-induced apoptosis in HCT116 colon carcinoma cells. Apoptosis. 2007;12:411–21. https://doi.org/10.1007/s10495-006-0576-9.CrossRefPubMed

19.

Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY. p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res. 2008;68(5):1369–77. https://doi.org/10.1158/0008-5472.can-07-5222.CrossRefPubMed

20.

Purohit V, Rapaka R, Kwon OS, Song BJ. Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sci. 2013;92(1):3–9. https://doi.org/10.1016/j.lfs.2012.10.009.CrossRefPubMed

21.

Liu J, Grogan L, Nau MM, Allegra CJ, Chu E, Wright JJ. Physical interaction between p53 and primary response gene Egr-1. Int J Oncol. 2001;18(4):863–70. https://doi.org/10.3892/ijo.18.4.863.CrossRefPubMed

22.

Sauer L, Gitenay D, Vo C, Baron VT. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene. 2010;29(18):2628–37. https://doi.org/10.1038/onc.2010.24.CrossRefPubMedPubMedCentral

23.

Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ. Expression of early growth response genes in human prostate cancer. Cancer Res. 1998;58(11):2461–8.PubMed

24.

Park SY, Kim JY, Lee SM, et al. Expression of early growth response gene-1 in precancerous lesions of gastric cancer. Oncol Lett. 2016;12:2710–5. https://doi.org/10.3892/ol.2016.4962.CrossRefPubMedPubMedCentral

25.

Schwachtgen JL, Houston P, Campbell C, et al. Fluid shear stress activation of egr-1 transcription in cultured human endothelial and epithelial cells is mediated via the extracellular signal-related kinase 1/2 mitogen-activated protein kinase pathway. J Clin Invest. 1998;101:2540–9. https://doi.org/10.1172/jci1404.CrossRefPubMedPubMedCentral

26.

Burnatowska-Hledin MA, Kossoris JB, Van Dort CJ, et al. T47D breast cancer cell growth is inhibited by expression of VACM-1, a cul-5 gene. Biochem Biophys Res Commun. 2004;319:817–25. https://doi.org/10.1016/j.bbrc.2004.05.057.CrossRefPubMed

27.

Park SY, Kim JY, Lee SM, Chung JO, Lee KH, Jun CH, Lee YH. Expression of early growth response gene-1 in precancerous lesions of gastric cancer. Oncol Lett. 2016;12(4):2710–5. https://doi.org/10.3892/ol.2016.4962.CrossRefPubMedPubMedCentral

28.

Lei B, Sun S, Zhang X, Feng C, Xu J, Wen Y, Yu Y. Bisphenol AF exerts estrogenic activity in MCF-7cells through activation of Erk and PI3 K/Akt signals via GPER signaling pathway. Chemosphere. 2019;220:362–70. https://doi.org/10.1016/j.chemosphere.2018.12.122.CrossRefPubMed

29.

Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, Kanashiro CA. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer. 2005;41(17):2735–44. https://doi.org/10.1016/j.ejca.2005.08.022.CrossRefPubMed

30.

Xiao D, Chinnappan D, Pestell R, Albanese C, Weber HC. Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells. Cancer Res. 2005;65(21):9934–42. https://doi.org/10.1158/0008-5472.can-05-1830.CrossRefPubMed

31.

Jablonski SA, Robinson-Drummer PA, Schreiber WB, Asok A. Impairment of the context preexposure facilitation effect in juvenile rats by neonatal alcohol exposure is associated with decreased Egr-1 mRNA expression in the prefrontal cortex. Behav Neurosci. 2018;132(6):497–511. https://doi.org/10.1037/bne0000272.CrossRefPubMedPubMedCentral

32.

Chen YL, Lin PC, Chen SP, Lin CC, Tsai NM, Cheng YL, Harn HJ. Activation of nonsteroidal anti-inflammatory drug-activated gene-1 via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase revealed a isochaihulactone-triggered apoptotic pathway in human lung cancer A549 cells. J Pharmacol Exp Ther. 2007;323(2):746–56. https://doi.org/10.1124/jpet.107.126193.CrossRefPubMed

33.

Shin DY, Kim GY, Kim ND, Jung JH, Kim SK, Kang HS, Choi YH. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells. Oncol Rep. 2008;19(2):517–26.PubMed

34.

Chintharlapalli S, Papineni S, Baek SJ, et al. 1,1-Bis(3’-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol. 2005;68:1782–92. https://doi.org/10.1124/mol.105.017046.CrossRefPubMed

35.

Moorehead RA, Hojilla CV, De Belle I, et al. Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem. 2003;278:50422–7. https://doi.org/10.1074/jbc.m306894200.CrossRefPubMed

36.

Cesaratto L, Calligaris SD, Vascotto C, et al. Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway. J Mol Med (Berl). 2007;85:1099–112. https://doi.org/10.1007/s00109-007-0204-3.CrossRef

37.

Pan L, Matloob AF, Du J, et al. Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrate-induced and 5-aza-2’-deoxycytidine-induced PTEN upregulation. FEBS J. 2010;277:989–99. https://doi.org/10.1111/j.1742-4658.2009.07542.x.CrossRefPubMed

38.

Scheel C. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012;22:396–403. https://doi.org/10.1016/j.semcancer.2012.04.001.CrossRefPubMedPubMedCentral

39.

Du J. High PKD2 predicts poor prognosis in lung adenocarcinoma via promoting Epithelial-mesenchymal Transition. Sci Rep. 2019;9(1):1324. https://doi.org/10.1038/s41598-018-37285-0.CrossRefPubMedPubMedCentral

40.

Kuo PL, Chen YH, Chen TC, Shen KH, Hsu YL. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. J Cell Physiol. 2011;226(5):1224–31. https://doi.org/10.1002/jcp.22445.CrossRefPubMed

41.

Cheng JC, Chang HM, Leung PC. Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene. 2013;32(8):1041–9. https://doi.org/10.1038/onc.2012.127.CrossRefPubMed

42.

Forte E, Chimenti I, Rosa P, et al. EMT/MET at the crossroad of stemness, regeneration and oncogenesis: the Ying-Yang Equilibrium recapitulated in cell spheroids. Cancers (Basel). 2017. https://doi.org/10.3390/cancers9080098.CrossRef

43.

Shao G, Liu Y, Ma T, et al. GCN5 inhibition prevents IL-6-induced prostate cancer metastases through PI3 K/PTEN/Akt signaling by inactivating Egr-1. Biosci Rep. 2018. https://doi.org/10.1042/bsr20180816.CrossRefPubMedPubMedCentral

44.

Wang W, Xiong Y, Ding X, et al. Cathepsin L activated by mutant p53 and Egr-1 promotes ionizing radiation-induced EMT in human NSCLC. J Exp Clin Cancer Res. 2019;38:61. https://doi.org/10.1186/s13046-019-1054-x.CrossRefPubMedPubMedCentral

45.

Wang LF, Liu YS, Yang B, Li P, Cheng XS, Xiao CX, Guleng B. The extracellular matrix protein mindin attenuates colon cancer progression by blocking angiogenesis via Egr-1-mediated regulation. Oncogene. 2018;37(5):601–15. https://doi.org/10.1038/onc.2017.359.CrossRefPubMed

46.

Ren B, Yee KO, Lawler J. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta. 2006;1765:178–88. https://doi.org/10.1016/j.bbcan.2005.11.002.CrossRefPubMed

47.

Zhao HY, Ooyama A, Yamamoto M, et al. Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil. Cancer Res. 2008;68:7035–41. https://doi.org/10.1158/0008-5472.can-07-6496.CrossRefPubMed

48.

Lucerna M, Pomyje J, Mechtcheriakova D, et al. Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res. 2006;66:6708–13. https://doi.org/10.1158/0008-5472.can-05-2732.CrossRefPubMedPubMedCentral

49.

Ganesan P, Matsubara K, Sugawara T. Marine algal carotenoids inhibit angiogenesis by down-regulating FGF-2-mediated intracellular signals in vascular endothelial cells. Mol Cell Biochem. 2013;380:1–9. https://doi.org/10.1007/s11010-013-1651-5.CrossRefPubMed

50.

Brown KC, Lau JK, Dom AM, et al. MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis. 2012;15:99–114. https://doi.org/10.1007/s10456-011-9246-9.CrossRefPubMed

51.

Eyries M, Siegfried G, Ciumas M, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res. 2008;103:432–40. https://doi.org/10.1161/circresaha.108.179333.CrossRefPubMed

52.

Shweiki D, Itin A, Soffer D. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843–5. https://doi.org/10.1038/359843a0.CrossRefPubMed

53.

Michiels C, Arnould T. Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta. 2000;1497:1–10.CrossRef

54.

Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:3721–32.CrossRef

55.

Ji RC. Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett. 2014;346(1):6–16. https://doi.org/10.1016/j.canlet.2013.12.001.CrossRefPubMed

56.

Shimoyamada H, Yazawa T, Sato H, et al. Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells. Am J Pathol. 2010;177:70–83. https://doi.org/10.2353/ajpath.2010.091164.CrossRefPubMedPubMedCentral

57.

Shin SY, Lee JM, Lim Y, Lee YH. Transcriptional regulation of the growth-regulated oncogene alpha gene by early growth response protein-1 in response to tumor necrosis factor alpha stimulation. Biochim Biophys Acta. 2013;1829(10):1066–74. https://doi.org/10.1016/j.bbagrm.2013.07.005.CrossRefPubMed

58.

Shin SY, Kim JH, Baker A, Lim Y, Lee YH. Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor alpha. Mol Cancer Res. 2010;8(4):507–19. https://doi.org/10.1158/1541-7786.mcr-09-0454.CrossRefPubMed

59.

Spencer JA, Major ML, Misra RP. Basic fibroblast growth factor activates serum response factor gene expression by multiple distinct signaling mechanisms. Mol Cell Biol. 1999;19(6):3977–88. https://doi.org/10.1128/mcb.19.6.3977.CrossRefPubMedPubMedCentral

60.

Duan WR, Ito M, Park Y, Maizels ET, Hunzicker-Dunn M, Jameson JL. GnRH regulates early growth response protein 1 transcription through multiple promoter elements. Mol Endocrinol. 2002;16(2):221–33. https://doi.org/10.1210/mend.16.2.0779.CrossRefPubMed

61.

Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R, Kufe DW. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA. 1993;90(6):2419–22. https://doi.org/10.1073/pnas.90.6.2419.CrossRefPubMed

62.

Seung LP, Mauceri HJ, Beckett MA, Hallahan DE, Hellman S, Weichselbaum RR. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 1995;55(23):5561–5.PubMed

63.

Bickenbach KA, Veerapong J, Shao MY, Mauceri HJ, Posner MC, Kron SJ, Weichselbaum RR. Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther. 2008;15(3):133–9. https://doi.org/10.1038/sj.cgt.7701103.CrossRefPubMed

64.

Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther. 2002;9(20):1403–11. https://doi.org/10.1038/sj.gt.3301823.CrossRefPubMed

65.

Wang WD, Li R, Chen ZT, Li DZ, Duan YZ, Cao ZH. Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements. Cancer Sci. 2005;96(10):706–12. https://doi.org/10.1111/j.1349-7006.2005.00105.x.CrossRefPubMed

66.

Chen A, Xu J. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene. 2006;25:278–87. https://doi.org/10.1038/sj.onc.1209019.CrossRefPubMed

67.

Chen QY, Jiao DM, Wang LF, et al. Curcumin inhibits proliferation-migration of NSCLC by steering crosstalk between a Wnt signaling pathway and an adherens junction via EGR-1. Mol BioSyst. 2015;11:859–68. https://doi.org/10.1039/c4mb00336e.CrossRefPubMed

68.

Yang MH, Kim J, Khan IA, et al. Nonsteroidal anti-inflammatory drug activated gene-1 (NAG-1) modulators from natural products as anti-cancer agents. Life Sci. 2014;100:75–84. https://doi.org/10.1016/j.lfs.2014.01.075.CrossRefPubMed

69.

Jeung YJ, Kim HG, Ahn J, et al. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300. Biochim Biophys Acta. 2016;1863:2584–93. https://doi.org/10.1016/j.bbamcr.2016.07.005.CrossRefPubMed

70.

Xia Y, Lian S, Khoi PN, et al. Chrysin inhibits cell invasion by inhibition of Recepteur d’origine Nantais via suppressing early growth response-1 and NF-κB transcription factor activities in gastric cancer cells. Int J Oncol. 2015;46:1835–43. https://doi.org/10.3892/ijo.2015.2847.CrossRefPubMed

71.

Han MH, Kim GY, Yoo YH. Sanguinarine induces apoptosis in human colorectal cancer HCT-116 cells through ROS-mediated Egr-1 activation and mitochondrial dysfunction. Toxicol Lett. 2013;220:157–66. https://doi.org/10.1016/j.toxlet.2013.04.020.CrossRefPubMed

72.

Zcharia E, Atzmon R, Nagler A, et al. Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor. Anticancer Drugs. 2012;23:1022–31. https://doi.org/10.1097/cad.0b013e328357d186.CrossRefPubMed

73.

Baek SJ, Kim JS, Nixon JB, et al. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem. 2004;279:6883–92. https://doi.org/10.1074/jbc.m305295200.CrossRefPubMed

74.

Baek SJ, Kim JS, Nixon JB, et al. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem. 2004;279(8):6883–92. https://doi.org/10.1074/jbc.m305295200.CrossRefPubMed

75.

Chen YL, Lin PC, Chen SP, et al. Activation of nonsteroidal anti-inflammatory drug-activated gene-1 via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase revealed a isochaihulactone-triggered apoptotic pathway in human lung cancer A549 cells. J Pharmacol Exp Ther. 2007;323:746–56. https://doi.org/10.1124/jpet.107.126193.CrossRefPubMed

76.

Chiu SC, Wang MJ, Yang HH, et al. Activation of NAG-1 via JNK signaling revealed an isochaihulactone-triggered cell death in human LNCaP prostate cancer cells. BMC Cancer. 2011;11:146. https://doi.org/10.1186/1471-2407-11-146.CrossRefPubMedPubMedCentral

77.

Shin DY, Kim GY, Li W, et al. Implication of intracellular ROS formation, caspase-3 activation and Egr-1 induction in platycodon D-induced apoptosis of U937 human leukemia cells. Biomed Pharmacother. 2009;63:86–94. https://doi.org/10.1016/j.biopha.2008.08.001.CrossRefPubMed

78.

Auyeung KK. Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation. Int J Mol Med. 2009;24:571–7.PubMed

79.

Shin SY, Kim JH, Lee JH, et al. 2’-Hydroxyflavanone induces apoptosis through Egr-1 involving expression of Bax, p21, and NAG-1 in colon cancer cells. Mol Nutr Food Res. 2012;56:761–74. https://doi.org/10.1002/mnfr.201100651.CrossRefPubMed

Title: Friend or foe, the role of EGR-1 in cancer
Authors: Tong-tong Li
Man-ru Liu
Dong-sheng Pei
Publication date: 01-01-2020
Publisher: Springer US
Keyword: Metastasis
Published in: Medical Oncology / Issue 1/2020
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-019-1333-6

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study

Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors

Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation

Mitotic checkpoint kinase Mps1/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKCα/ERK1/2 and PI3K/Akt pathway

Cancer gene profiling explores the possible precision medicine for diffuse-type gastric adenocarcinoma

Venous thromboprophylaxis in urological cancer surgery

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage